Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of May 2014, specifically dated May 7, 2014. The registrant is a foreign private issuer based in Petach-Tikva, Israel, reporting pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative performance data.
Material Changes
The primary material event disclosed is the issuance of a patent in the European Union for the treatment of liver function following surgery. This represents a significant milestone in the company's intellectual property portfolio.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the announcement of the patent grant. No unusual items were reported in this specific document.
Investor Verification Checklist
- Verify the scope and validity of the European Union patent for post-surgical liver function treatment.
- Review the attached press release (Exhibit 99.1) for details on the patent's commercial potential.
- Check subsequent filings for financial impact or clinical trial updates related to this patent.